---
layout: default
title: Alpha Lipoic Acid Ammonium Bromide Ammonium Carbon
parent: 僅模型預測 (L5)
nav_order: 261
evidence_level: L5
indication_count: 0
---

# Alpha Lipoic Acid Ammonium Bromide Ammonium Carbon
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex: No Repurposing Prediction Available

> **Note:** The INN for this candidate covers 18 components: Alpha Lipoic Acid, Ammonium Bromide, Ammonium Carbonate, Antimony Trisulfide, Artemisia Cina Pre-Flowering Top, Bos Taurus Hypothalamus, Bos Taurus Pituitary Gland Posterior, Delphinium Staphisagria Seed, Fucus Vesiculosus, Garcinia Gummi-Gutta Fruit, Lycopodium Clavatum Spore, Nerium Oleander Whole, Olea Europaea Flower, Oyster Shell Calcium Carbonate Crude, Phosphorus, Semecarpus Anacardium Juice, Sodium Chloride, Thyroid Unspecified.

---

## One-Sentence Summary

This 18-component product contains a mixture of botanical, homeopathic, and glandular ingredients — a profile consistent with naturopathic weight management or thyroid support formulations.
However, **no original indication is recorded** in any regulatory database, and the TxGNN model generated **no repurposing predictions** for this candidate.
As a result, evidence-based evaluation cannot proceed until foundational data are collected.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded (no regulatory approvals found) |
| Predicted New Indication | None — TxGNN produced no prediction for this candidate |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (prerequisite data absent) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model requires a mapped **DrugBank ID** and at least one recognized disease association in the knowledge graph to generate a repurposing score.
This candidate has neither: `drugbank_id` is null, and `original_indications` is empty.

From the ingredient profile, the product appears to be a **homeopathic / naturopathic combination**:

- **Metabolic/weight management components**: Garcinia gummi-gutta (hydroxycitric acid source), Fucus vesiculosus (iodine/thyroid), Alpha lipoic acid (antioxidant, insulin sensitizer)
- **Glandular therapy components**: Thyroid (unspecified), Bos taurus hypothalamus, Bos taurus pituitary gland posterior
- **Classical homeopathic remedies**: Lycopodium clavatum, Phosphorus, Delphinium staphisagria, Nerium oleander, Semecarpus anacardium, Artemisia cina

Because none of these 18 components could be matched to a single DrugBank entry as a unit, the pipeline treated the combined INN string as an unknown entity and produced no candidates.

---

## Safety Considerations

Please refer to the package insert for safety information.

> No DDI records were found. Key warnings and contraindications data are unavailable and must be sourced from the original product labeling before any clinical evaluation begins.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The candidate lacks the two minimum inputs needed for TxGNN evaluation — a DrugBank ID and a documented original indication — and has zero regulatory approvals in any jurisdiction. There is no basis for a repurposing assessment at this stage.

**To proceed, the following is needed:**

1. **Disaggregate the compound**: Evaluate each of the 18 active ingredients individually through TxGNN, or identify the single primary active component for the repurposing query.
2. **Establish original indication**: Retrieve the product's labeled indication from its country of origin or manufacturer documentation to anchor the evaluation.
3. **DrugBank mapping**: Attempt individual DrugBank ID matching for pharmacologically active components (Alpha Lipoic Acid, Fucus Vesiculosus, Garcinia Gummi-Gutta, Thyroid) that have established DrugBank entries.
4. **Safety data collection**: Download the original product insert (or equivalent label) to resolve the Blocking data gap (DG001) for key warnings and contraindications.
5. **Regulatory status clarification**: Confirm whether this product is registered in any jurisdiction as a dietary supplement, homeopathic product, or pharmaceutical, since the regulatory pathway materially affects what evidence standards apply.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

